Current Issues Link

Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive non-muscle invasive bladder cancer.

The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.

Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.

"We thought there might be a preventive effect towards the development from CHIP to CCUS to MDS, so it’s a sort of a continuum," said Kirsten Grønbæk, MD, PhD.

Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in relapsed multiple myeloma.

Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.

Industry payments to oncologists were associated with greater use of the promoted treatment, whether or not it was guideline-preferred for the patient’s cancer.

The phase 2/3 AHEAD-MERIT trial will continue to assess overall survival among patients who received BNT113 plus pembrolizumab for head and neck cancer.